Extracorporeal life support in severe drug intoxication: a retrospective cohort study of seventeen cases.
BACKGROUND
Cardiovascular failure is the leading cause of death in severe acute drug intoxication. In this setting, we report the feasibility, complications, and outcome of emergency extracorporeal life support (ECLS) in refractory shock or cardiac arrest following a drug overdose.


METHODS
This is a retrospective cohort study of 17 patients admitted over a 10-year period for prolonged cardiac arrest or refractory shock following a drug overdose and not responding to optimal conventional treatment. Patients were evaluated in the medical ICU and cardiovascular surgery department of a university hospital. ECLS implantation used a centrifugal pump connected to a hollow-fiber membrane oxygenator and was performed in the operating room (n = 13), intensive care unit (n = 3), or emergency department (n = 1). ECLS was employed for refractory shock and prolonged cardiac arrest in 10 and 7 cases, respectively.


RESULTS
The mean duration of external cardiac massage was 101 +/- 55 minutes. Fifteen patients had ingested cardiotoxic drugs, including 11 cases of drugs with membrane stabilizing activity. Time from hospital admission to initiation of ECLS was 6.4 +/- 7.0 hours. Time to ECLS implant was 58 +/- 11 minutes. The mean ECLS flow rate was 3.45 +/- 0.45 L/min. The average ECLS duration was 4.5 +/- 2.4 days. Early complications included limb ischemia (n = 6), femoral thrombus (n = 1), cava inferior thrombus (n = 1), and severe bleeding at the site of cannulation (n = 2). Fifteen patients were weaned off ECLS support and 13 (76%) were discharged to hospital without sequelae.


CONCLUSIONS
Based on our experience, we consider ECLS as a last resort, efficient, and relatively safe therapeutic option in this population. However, the uncontrolled nature of our data requires careful interpretation.
Daubin
Cédric
C
Department of Medical Intensive Care, Caen University Hospital, avenue Côte de Nacre, Caen Cedex 14033, France. daubin-c@chu-caen.fr
Lehoux
Philippe
P
Ivascau
Calin
C
Tasle
Marine
M
Bousta
Mehdi
M
Lepage
Olivier
O
Quentin
Charlotte
C
Massetti
Massimo
M
Charbonneau
Pierre
P
D002315:Cardiopulmonary Bypass; D015331:Cohort Studies; D064420:Drug-Related Side Effects and Adverse Reactions / Q000150:complications / Q000628:therapy*; D005240:Feasibility Studies; D006801:Humans; D016896:Treatment Outcome
J Clin Pharmacol. 1996 Aug;36(8):760-3
8877682
Am J Emerg Med. 1994 Jul;12(4):456-8
8031434
Vet Hum Toxicol. 1999 Oct;41(5):326-8
10509440
Lancet. 1986 Jun 21;1(8495):1414-7
2872519
Ann Thorac Surg. 1999 Aug;68(2):655-61
10475466
Anaesthesia. 1991 Sep;46(9):744-6
1928675
Crit Care Med. 2001 Apr;29(4):887-90
11373489
Clin Toxicol (Phila). 2007 Dec;45(8):961-4
17852155
Crit Care Med. 1998 Nov;26(11):1793-800
9824069
Toxicol Rev. 2004;23(4):223-38
15898828
Ann Emerg Med. 1997 May;29(5):680-2
9140253
JAMA. 1993 Dec 22-29;270(24):2957-63
8254858
J Thorac Cardiovasc Surg. 2000 Aug;120(2):424-5
10917971
Ann Thorac Surg. 2005 Jan;79(1):178-83; discussion 183-4
15620939
Arch Mal Coeur Vaiss. 2001 Dec;94(12):1386-92
11828924
J Cardiol. 1998 Aug;32(2):95-100
9752618
Intensive Care Med. 2007 May;33(5):758-764
17342517
Crit Care Med. 1993 Apr;21(4):625-7
8472584
Acad Emerg Med. 2004 Jan;11(1):71-4
14709431
Ann Fr Anesth Reanim. 2009 Feb;28(2):182-90
19232884
Pediatr Emerg Care. 1997 Apr;13(2):111-3
9127419
J Toxicol Clin Toxicol. 1990;28(4):433-44
2176700
Crit Care Med. 1999 Dec;27(12):2818-23
10628632
Anaesth Intensive Care. 1999 Aug;27(4):405-8
10470398
Clin Toxicol (Phila). 2006;44(6-7):803-932
17015284
Eur J Emerg Med. 2007 Apr;14(2):120-2
17496693
Ann Emerg Med. 1991 Aug;20(8):861-74
1854070
Emerg Med J. 2006 Apr;23(4):246-50
16549566
Crit Care. 2007;11(2):207
17367544
Ann Emerg Med. 1994 Mar;23(3):480-6
8135422
J Intensive Care Med. 2007 Nov-Dec;22(6):381-5
18062140
Eur J Clin Pharmacol. 1982;22(2):129-35
7094983
Intensive Care Med. 2006 Sep;32(9):1409-13
16835785